Infant monkey hyperexcitability after prenatal exposure to antiepileptic compounds

Epilepsia

Volumn 37, Issue 10, 1996, Pages 991-999

  Phillips, Nona K ^a   Lockard, Joan S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antiepileptic drugs; Epilepsy; Hyperexcitability; Infant development; Pregnancy

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; PHENYTOIN; STIRIPENTOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; CONTROLLED STUDY; HYPERACTIVITY; MATERNAL DISEASE; MEMORY; MONKEY; NONHUMAN; POSTNATAL DEVELOPMENT; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RATING SCALE; STIMULUS RESPONSE; TERATOGENICITY;

EID: 0029788682     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1996.tb00538.x     Document Type: Article

References (68)

1. Phillips NK, Lockard JS. Phenytoin and/or stiripentol in pregnancy: infant monkey hyperexcitability. Epilepsia 1993; 34:1117-22.
2. Oguni M, Dansky L, Andermann E, Sherwin A, Andermann F. Improved pregnancy outcome in epileptic women in the last decade: relationship to maternal anticonvulsant therapy. Brain Dev 1992;14:371-80.
3. Kaneko S, Otani K, Kondo T, et al. Teratogenicity of antiepileptic drugs and drug specific malformations. Jpn J Psychiatry Neurol 1993;47:306-8.
4. Scolnick D, Nulman I, Rovet J, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994;271:767-70.
5. Dam M, Christiansen J, Munck O, Mygind KI. Antiepileptic drugs: metabolism in pregnancy. Clin Pharmacokinet 1979;4:53-62.
6. Murasaki M, Okamoto K, Takahashi A, Nagai T. Psychomotor status - a female case in the 34th week of pregnancy. Folia Psychiatr Neurol (Japan), 1983;37:435-42.
7. Otani K. Risk factors for the increased seizure frequency during pregnancy and puerperium. Folia Psychiatr Neurol (Japan) 1985;39:33-44.
8. Hill RM, Verniaud WM, Rettig GM, Tennyson LM, Craig JP. Relationship between antiepileptic drug exposure of the infant and developmental potential. In: Janz D, Dam M, Richens A, Bossi L, Helge H, Schmidt D, eds. Epilepsy, pregnancy and the child. New York: Raven Press, 1982;409-17.
9. Van Dyke DC, Hodge SE, Heide F, Hill LR. Family studies in fetal phenytoin exposure. J Pediatr 1988;113:301-6.
10. Yerby MS. Epilepsy and pregnancy. New issues for an old disorder. Neurol Clin 1993;11:777-86.
11. Aldenkamp AP, Alpherts WCJ, Dekker MJA, Overweg J. Neuropsychological aspects of learning disabilities in epilepsy. Epilepsia 1990;31(suppl 4):S9-20.
12. Rugland AL. Neuropsychological assessment of cognitive functioning in children with epilepsy. Epilepsia 1990;31 (suppl 4):S41-4.
13. Lewis RB, Kass CE. Labelling and recall in learning disabled students. J Learning Disab 1982;15:238-41.
14. Vorhees CV. Fetal anticonvulsant syndrome in rats: dose- and period-response relationships of prenatal diphenylhydantoin, trimethadione and phenobarbital exposure on the structural and functional development of the offspring. J Pharmacol Exp Ther 1983;227:274-87.
15. Vorhees CV. Fetal anticonvulsant syndrome in rats: effects on postnatal behavior and brain amino acid content. Neurobehav Toxicol Teratol 1985;7:471-82.
16. Vorhees CV. Developmental effects of anticonvulsants. Neurotoxicology 1986;7:235-44.
17. Vorhees CV. Fetal anticonvulsant exposure: effects on behavioral and physical development. Ann NY Acad Sci 1986;477:49-62.
18. Vorhees CV. Behavioral teratogenicity of valproic acid: selective effects on behavior after prenatal exposure to rats. Psychopharmacology (Berlin) 1987;92:173-9.
19. Vorhees CV. Fetal hydantoin syndrome in rats: dose-effect relationships of prenatal phenytoin on postnatal development and behavior. Teratology 1987;35:287-303.
20. Vorhees CV. Maze learning in rats: a comparison of performance in two water mazes in progeny prenatally exposed to different doses of phenytoin. Neurotoxicol Teratol 1987;9: 235-41.
21. Eluma FO, Sucheston ME, Hayes TG, Paulson RB. Teratogenic effects of dosage levels and time of administration of carbamazepine, sodium valproate, and diphenylhydantoin on craniofacial development in the CD-1 mouse fetus. J Craniofac Genet Dev Biol 1984;4:191-210.
22. Finnell RH, Chernoff GF. Variable patterns of malformation in the mouse fetal hydantoin syndrome. Am J Med Gent 1984;19:463-71.
23. Finnell RH, Baer JF. Congenital defects among the offspring of epileptic fathers: role of the genotype and phenytoin therapy in a mouse model. Epilepsia 1986;27:697-705.
24. Finnell RH, Mohl VK, Bennett GD, Taylor SM. Failure of epoxide formation to influence carbamazepine-induced teratogenesis in a mouse model. Teratogenesis Carcinog Mutagen 1986;6:393-401.
25. Finnell RH, Shields HE, Chernoff GF. Variable patterns in anticonvulsant drug-induced malformations in mice: comparisons of phenytoin and phenobarbital. Teratogenesis Carcinog Mutagen 1987;7:541-9.
26. Phillips NK, Lockard JS. A gestational monkey model: phenytoin versus seizures and neonatal outcome. In: Porter RJ, Mattson RH, Ward AA Jr, eds. Advances in epileptology: 15th Epilepsy International Symposium. New York: Raven Press, 1984:325-30.
27. Phillips NK, Lockard JS. Social and locomotor development after phenytoin exposure in neonatal monkeys. Epilepsia 1985;26:546.
28. Phillips NK, Lockard JS. A gestational monkey model: effects of phenytoin versus seizures on neonatal outcome. Epilepsia 1985;26:697-703.
29. Phillips NK, Lockard JS. Sibling developmental comparisons and magnetic resonance images on a rhesus infant prenatally exposed to valproate. Epilepsia 1986;27:626.
30. Phillips NK, Lockard JS. Visual recognition memory in infant monkeys prenatally exposed to phenytoin or stiripentol, Proceedings of the 18th International Epilepsy Congress, Delhi, India, October 17-20, 1989.
31. Phillips NK, Lockard JS. Stiripentol, phenytoin, valproate and pregnancy in monkey. Epilepsia 1989;30:666.
32. Phillips NK, Lockard JS. Object permanence in monkey infants prenatally exposed to phenytoin or stiripentol. Epilepsia 1990;31:600.
33. Shapiro S, Hartz SC, Siskind V, et al. Anticonvulsants and parental epilepsy in the development of birth defects. Lancet 1976;1:272-5.
34. Nakane Y. Factors influencing the risk of malformation among infants of epileptic mothers. In: Janz D, Bossi L, Dam M, Helge H, Richens A, Schmidt S, eds. Epilepsy, pregnancy and the child. New York: Raven Press, 1982:259-65.
35. Lindhout D, Meinardi H, Barth PG. Hazards of fetal exposure to drug combinations. In: Janz D, Bossi L, Dam M, Helge H, Richens A, Schmidt S, eds. Epilepsy, pregnancy and the child. New York: Raven Press, 1982:275-81.
36. Lindhout D, Hoppener RJ, Meinardi H. Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (or carbamazepine). Epilepsia 1984;25:77-83.
37. Kaneko S, Fukushima Y, Sato T, et al. Hazards of fetal exposure to antiepileptic drugs: a preliminary report. In: Sato T, Shinagawa S, eds. Antiepileptic drugs and pregnancy. Amsterdam: Excerpta Medica, 1984:132-8.
38. Kaneko S, Otani K, Fukushima Y, et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia 1988;29:459-67.
39. Yerby MS. Pregnancy, teratogenesis, and epilepsy. Neurol Clin 1994;12:749-71.
40. Lin H, Levy RH. Pharmacokinetic profile of a new anticonvulsant, stiripentol, in the rhesus monkey. Epilepsia 1983; 24:692-702.
41. Wegmann R, Ilies A, Aurousseau M. Pharmaco-cellular enzymology of the mode of action of the stiripentol during cariazolic epilepsy - III. The metabolism of lipids, proteins, nucleoproteins and proteoglycans. Cell Mol Biol 1987;23: 455-80.
42. Mesnil M, Testa B, Jenner P. In vitro inhibition by stiripentol of rat brain cytochrome P-450-mediated naphthalene hydroxylation. Xenobiotica 1988;18:1097-106.
43. Finnell RH, Levy RH, Kerr BM. Decrease in phenytoin teratogenicity by coadministration of stiripentol. Epilepsia 1990;31:620.
44. Jones KL, Lacro RV, Johnson KA, Adams J. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989;320:1661-6.
45. Lockard JS, Levy RH, Congdon WC, Phillips NK. Carbamazepine plus stiripentol in pregnancy: reduced CBZ epoxide formation. Epilepsia 1990;35:600.
46. Gunderson VM. Development of cross-modal recognition in infant pigtail monkeys (Macaca nemestrina). Dev Psychol 1983;19:398-404.
47. Gunderson VM, Sackett GP. Development of pattern recognition in infant pigtailed macaques (Macaca nemestrina). Dev Psychol 1984;20:418-26.
48. Gunderson VM, Swartz KB. Visual recognition in infant pigtailed macaques after a 24 hour delay. Am J Primatol 1985; 8:259-64.
49. Gunderson VM, Swartz KB. The effects of familiarization time on visual recognition memory in infant pigtailed macaques (Macaca nemestrina). Dev Psychol 1986;22:477-80.
50. Gunderson VM, Rose SA, Grant-Webster KS. Cross-modal transfer in high- and low-risk infant pigtailed macaque monkeys. Dev Psychol 1990;26:576-81.
51. Sands SF, Wright AA. Primate memory: retention of serial list items by a rhesus monkey. Science 1980;209:938-40.
52. Sands SF, Wright AA. Monkey and human memory pictorial scanning. Science 1982;216:1333-4.
53. Jacobson SW, Fein GG, Jacobson JS, Schwartz PM, Dowler JK. The effect of intrauterine PCB exposure on visual recognition memory. Child Dev 1985;56:853-60.
54. Rose SA, Wallace IF. Cross-modal and intramodal transfer as predictors of mental development in full-term and preterm infants. Dev Psychol 1985;21:949-62.
55. Burbacher TM, Grant KS, Mottet NK. Retarded object permanence development in methylmercury exposed Macaca fascicularis infants. Dev Psychol 1986;22:771-6.
56. Burbacher TM, Mohamed MK, Mottett NK. Methylmercury effects on reproduction and offspring size at birth. Reprod Toxicol 1988;1:267-78.
57. Gunderson VM, Grant KS, Burbacher TM, Fagan JF, Mottet NK. The effect of low-level prenatal methylmercury ex- posure on visual recognition memory in infant crab-eating macaques. Child Dev 1986;57:1076-83.
58. Gunderson VM, Fagan JF, Grant-Webster KS. Visual recognition memory in high- and low-risk infant pigtailed macaques (Macaca nemestrina). Dev Psychol 1987;23:671-5.
59. Gunderson VM, Grant-Webster KS, Burbacher TM, Mottet NK. Visual recognition memory deficits in methylmercury-exposed Macaca fascicularis infants. Neurotoxicol Teratol 1988;10:373-9.
60. Fagan JF, McGrath SK. Infant recognition memory and later intelligence. Intelligence 1981;5:121-30.
61. Sackett GP, Gunderson V, Baldwin B. Studying the ontogeny of primate behavior. In: Fobes JL, King JE, eds. Primate behavior. New York: Academic Press, 1982:135-69.
62. Lockard JS, Levy RH, Uhlir V, Farquhar JA. Interactions of phenytoin and phenobarbital in terms of order and temporal spacing of administration in monkeys. Epilepsia 1976; 17:481-5.
63. Lockard JS, Levy RH. Carbamazepine plus stiripentol: is polytherapy by design possible? Epilepsia 1988;29:476-81.
64. Lockard JS. EEG quantification of drug level effects in monkey model of partial epilepsy. In: Buser PA, Cobb WA, Okuma T, eds. Kyoto Symposia (EEG suppl. no. 36). Amsterdam: Elsevier Biomedical Press, 1982:487-502.
65. Harris AB, Lockard JS. Macaca fascicularis: alternative epileptic model. Life Sciences 1979;25:281-6.
66. Lockard JS, Levy RH, DuCharme LL, Congdon WC, Patel IH. Carbamazepine revisited in a monkey model [Short communication]. Epilepsia 1979;20:169-73.
67. Green JR, Friel P, Amick-Corkill JA. Methods for gas-liquid Chromatographic determinations of carbamazepine, phenytoin, phenobarbitone, and primidone. In: Meijer JWA, Meinardi H, Gardner-Thorpe C, van der Kleijn E, eds. Methods of analysis of anti-epileptic drugs. Amsterdam: Excerpta Medica, 1973:169-80.
68. Adams J, Vorhees CV, Middaugh LD. Neurotoxicol Teratol 1990;12:203-14.